Journal ArticleDOI
Siponimod for the treatment of secondary progressive multiple sclerosis.
Reads0
Chats0
TLDR
Siponimod may reduce the activity of the disease and has a modest effect on the gradual disability accrual, and if approved, it may become one of the few available therapy options for secondary progressive MS.Abstract:
Introduction: Multiple sclerosis (MS) is a chronic central nervous system immune-mediated disease with an important inflammatory component associated with focal demyelination and widespread neurode...read more
Citations
More filters
Journal Article
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
TL;DR: Although no treatment benefit was seen on the time to confirmed progression of disability, relapse- and MRI- related outcomes showed significant benefit with both dosing regimens tested, a result consistent with the outcomes of earlier clinical trials.
Journal ArticleDOI
Tailor-Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals.
Haibo Mei,Jianlin Han,Sarah White,Daniel J. Graham,Kunisuke Izawa,Tatsunori Sato,Santos Fustero,Nicholas A. Meanwell,Vadim A. Soloshonok,Vadim A. Soloshonok +9 more
TL;DR: This review profiles 39 selected compounds featuring both of these traits in the same molecule, the total synthesis, source of the corresponding amino acids and fluorinated residues, and the medicinal chemistry aspects and biological properties of the molecules.
Journal ArticleDOI
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
TL;DR: Investigating the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis over the last 20 years and assessing the influences on rising prices found an urgent need for clinicians, payers, and manufacturers in theUnited States to confront the soaring costs of DMTs.
Journal ArticleDOI
Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.
Beatriz Canibano,Dirk Deleu,Boulenouar Mesraoua,Gayane Melikyan,Faiza Ibrahim,Yolande Hanssens +5 more
TL;DR: Current evidence and recommendations for counseling and management of women with MS preconception, during pregnancy and postpartum are provided and the benefit of continuing natalizumab during the entire pregnancy may outweigh the risk of recurring disease activity.
Journal ArticleDOI
Health economics of disease-modifying therapy for multiple sclerosis in the United States.
TL;DR: The objective of this narrative review is to summarize economic issues related to MS DMTs, including trends in pricing, relative value, and effects on patient care in the United States.
References
More filters
Journal ArticleDOI
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Charles M. Poser,Donald W. Paty,Labe C. Scheinberg,W I McDonald,F A Davis,George C. Ebers,Kenneth P. Johnson,William A. Sibley,Donald H. Silberberg,Wallace W. Tourtellotte +9 more
TL;DR: Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS.
Journal ArticleDOI
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson,Brenda Banwell,Frederik Barkhof,Frederik Barkhof,William M. Carroll,Timothy Coetzee,Giancarlo Comi,Jorge Correale,Franz Fazekas,Massimo Filippi,Mark S. Freedman,Kazuo Fujihara,Steven L. Galetta,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Ruth Ann Marrie,Aaron E. Miller,David Miller,Xavier Montalban,Xavier Montalban,Ellen M. Mowry,Per Soelberg Sørensen,Mar Tintoré,Anthony Traboulsee,Maria Trojano,Bernard M. J. Uitdehaag,Sandra Vukusic,Sandra Vukusic,Emmanuelle Waubant,Brian G. Weinshenker,Stephen C. Reingold,Jeffrey A. Cohen +32 more
TL;DR: The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation.
Journal ArticleDOI
Defining the clinical course of multiple sclerosis Results of an international survey
TL;DR: An international survey of clinicians involved with MS revealed areas of consensus about some terms classically used to describe types of the disease and other areas for which there was lack of consensus and proposed standardized definitions for the most common clinical courses of patients with MS.
Journal ArticleDOI
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos,Ernst Wilhelm Radue,Paul O'Connor,Chris H. Polman,Reinhard Hohlfeld,Peter A. Calabresi,Krzysztof Selmaj,Catherine Agoropoulou,Malgorzata Leyk,Lixin Zhang-Auberson,Pascale Burtin +10 more
TL;DR: Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Journal ArticleDOI
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin,Stephen C. Reingold,Jeffrey A. Cohen,Gary Cutter,Per Soelberg Sørensen,Alan J. Thompson,Jerry S. Wolinsky,Laura J. Balcer,Brenda Banwell,Frederik Barkhof,Bruce F. Bebo,Peter A. Calabresi,Michel Clanet,Giancarlo Comi,Robert J. Fox,Mark S. Freedman,Andrew D. Goodman,Matilde Inglese,Ludwig Kappos,Bernd C. Kieseier,John A. Lincoln,Catherine Lubetzki,Aaron E. Miller,Xavier Montalban,Paul O'Connor,John Petkau,Carlo Pozzilli,Richard A. Rudick,Maria Pia Sormani,Olaf Stüve,Emmanuelle Waubant,Chris H. Polman +31 more
TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.